JP2016500001A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016500001A5 JP2016500001A5 JP2015531678A JP2015531678A JP2016500001A5 JP 2016500001 A5 JP2016500001 A5 JP 2016500001A5 JP 2015531678 A JP2015531678 A JP 2015531678A JP 2015531678 A JP2015531678 A JP 2015531678A JP 2016500001 A5 JP2016500001 A5 JP 2016500001A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- protein
- residues
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000018102 proteins Nutrition 0.000 claims 22
- 102000004169 proteins and genes Human genes 0.000 claims 22
- 108090000623 proteins and genes Proteins 0.000 claims 22
- 150000001413 amino acids Chemical group 0.000 claims 19
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 12
- 229940024606 amino acid Drugs 0.000 claims 9
- 235000001014 amino acid Nutrition 0.000 claims 9
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 7
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 6
- 239000004471 Glycine Substances 0.000 claims 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 6
- 239000005557 antagonist Substances 0.000 claims 6
- 229960001230 asparagine Drugs 0.000 claims 6
- 235000009582 asparagine Nutrition 0.000 claims 6
- 238000012217 deletion Methods 0.000 claims 6
- 230000037430 deletion Effects 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 230000002209 hydrophobic effect Effects 0.000 claims 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 5
- 229960000310 isoleucine Drugs 0.000 claims 5
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 5
- 229930182817 methionine Natural products 0.000 claims 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 5
- 210000004899 c-terminal region Anatomy 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 239000000032 diagnostic agent Substances 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 206010068304 Congenital nephrogenic diabetes insipidus Diseases 0.000 claims 1
- 206010021036 Hyponatraemia Diseases 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000005118 Nephrogenic diabetes insipidus Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 230000002686 anti-diuretic effect Effects 0.000 claims 1
- 229940124538 antidiuretic agent Drugs 0.000 claims 1
- 239000003160 antidiuretic agent Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12306120.2A EP2708235A1 (en) | 2012-09-17 | 2012-09-17 | Peptide antagonists of the vasopressin-2 receptor |
| EP12306120.2 | 2012-09-17 | ||
| PCT/IB2013/058615 WO2014041526A1 (en) | 2012-09-17 | 2013-09-17 | Peptide antagonists of the vasopressin-2 receptor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016500001A JP2016500001A (ja) | 2016-01-07 |
| JP2016500001A5 true JP2016500001A5 (enExample) | 2016-11-04 |
| JP6392758B2 JP6392758B2 (ja) | 2018-09-19 |
Family
ID=46963639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015531678A Active JP6392758B2 (ja) | 2012-09-17 | 2013-09-17 | バソプレッシン−２レセプターのペプチドアンタゴニスト |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9631001B2 (enExample) |
| EP (2) | EP2708235A1 (enExample) |
| JP (1) | JP6392758B2 (enExample) |
| KR (1) | KR102135954B1 (enExample) |
| CN (1) | CN104684574B (enExample) |
| AU (1) | AU2013316700B2 (enExample) |
| BR (1) | BR112015005750B1 (enExample) |
| CA (1) | CA2884361C (enExample) |
| DK (1) | DK2895189T3 (enExample) |
| ES (1) | ES2664747T3 (enExample) |
| MX (1) | MX362664B (enExample) |
| NZ (1) | NZ706202A (enExample) |
| RU (1) | RU2015114320A (enExample) |
| WO (1) | WO2014041526A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021528476A (ja) * | 2018-06-28 | 2021-10-21 | サルアクア ダイアグノスティックス， インコーポレイテッド | ハプトグロビン関連タンパク質と関係する組成物および方法 |
| EP3929209A1 (en) | 2020-06-24 | 2021-12-29 | Commissariat à l'Energie Atomique et aux Energies Alternatives | Vasopressin-2 receptor antagonist peptides and uses thereof |
| CN115820734B (zh) * | 2022-11-11 | 2024-12-13 | 北京希诺谷生物科技有限公司 | 中枢性尿崩症疾病模型犬的建立方法 |
| CN116425888B (zh) * | 2023-04-24 | 2024-11-05 | 徐州医科大学 | 一种多肽tat-v2r1c及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5663143A (en) * | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
| SE0201863D0 (en) | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
| WO2007019267A1 (en) | 2005-08-03 | 2007-02-15 | Mineuet Therapeutics Ltd. | MODULATING THE KV1.1 VOLTAGE-GATED POTASSIUM CHANNEL IN T-CELLS FOR REGULATING THE SYNTHESIS AND SECRETION OF TUMOR NECROSIS FACTOR α (TNF-α) AND TREATING HUMAN DISEASES OR INJURIES MEDIATED BY DETRIMENTALLY HIGH OR LOW LEVELS OF TNF-α |
| US8343760B2 (en) * | 2008-06-05 | 2013-01-01 | University Of Maryland, Baltimore | p53 activator peptides |
-
2012
- 2012-09-17 EP EP12306120.2A patent/EP2708235A1/en not_active Withdrawn
-
2013
- 2013-09-17 WO PCT/IB2013/058615 patent/WO2014041526A1/en not_active Ceased
- 2013-09-17 NZ NZ706202A patent/NZ706202A/en unknown
- 2013-09-17 ES ES13801742.1T patent/ES2664747T3/es active Active
- 2013-09-17 MX MX2015003225A patent/MX362664B/es active IP Right Grant
- 2013-09-17 CA CA2884361A patent/CA2884361C/en active Active
- 2013-09-17 US US14/427,733 patent/US9631001B2/en active Active
- 2013-09-17 CN CN201380048382.9A patent/CN104684574B/zh active Active
- 2013-09-17 KR KR1020157009903A patent/KR102135954B1/ko active Active
- 2013-09-17 RU RU2015114320A patent/RU2015114320A/ru not_active Application Discontinuation
- 2013-09-17 AU AU2013316700A patent/AU2013316700B2/en active Active
- 2013-09-17 BR BR112015005750-0A patent/BR112015005750B1/pt active IP Right Grant
- 2013-09-17 JP JP2015531678A patent/JP6392758B2/ja active Active
- 2013-09-17 DK DK13801742.1T patent/DK2895189T3/en active
- 2013-09-17 EP EP13801742.1A patent/EP2895189B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI554280B (zh) | Ｈｌａ-ａ*１１０１限制性ｗｔ１胜肽之用途 | |
| FI3256579T3 (fi) | Kysteiiniproteaasi | |
| CA2880649C (en) | Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4) | |
| RU2016101711A (ru) | Высокостабильный т-клеточный рецептор и способ его получения и применения | |
| US10647742B2 (en) | Method for synthesizing etelcalcetide | |
| JP2014525901A5 (enExample) | ||
| RU2017119773A (ru) | Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение | |
| TW201702266A (zh) | 抗ｐａｃａｐ抗體及其用途 | |
| US20230212240A1 (en) | Wnt signaling agonist molecules | |
| JP2015134758A5 (enExample) | ||
| JP2016500001A5 (enExample) | ||
| JP7079779B2 (ja) | 操作されたｔｇｆベータ単量体およびｔｇｆベータシグナル伝達のためのそれらの使用 | |
| JP2012530060A5 (enExample) | ||
| JP2015508771A5 (enExample) | ||
| JP2015522264A5 (enExample) | ||
| JP2014506452A5 (enExample) | ||
| WO2021239949A1 (en) | Human recombinant monoclonal antibody against sars-cov-2 spike glycoprotein | |
| JP2011521661A5 (enExample) | ||
| JP2014533098A5 (enExample) | ||
| RU2015114320A (ru) | Пептидные антагонисты рецептора 2 вазопрессина | |
| CN119013034A (zh) | 用于治疗自身免疫性疾病的白细胞介素-2突变蛋白 | |
| CN102161692B (zh) | 改造的止血多肽及其运用 | |
| TW202122410A (zh) | 鈣敏感受體激動劑化合物及其應用 | |
| BRPI0517362A (pt) | polipeptìdeo, molécula de ácido nucleico purificada, vetor, célula hospedeira, anticorpo, métodos in vitro para diagnosticar uma doença em um paciente, composição farmacêutica, composição de vacina, uso de um polipeptìdeo, proteina de fusão, e, método para produção de proteìna | |
| JP2015533372A5 (enExample) |